166 related articles for article (PubMed ID: 16696593)
1. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light.
Yu G; Durduran T; Zhou C; Zhu TC; Finlay JC; Busch TM; Malkowicz SB; Hahn SM; Yodh AG
Photochem Photobiol; 2006; 82(5):1279-84. PubMed ID: 16696593
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.
Ross HM; Smelstoys JA; Davis GJ; Kapatkin AS; Del Piero F; Reineke E; Wang H; Zhu TC; Busch TM; Yodh AG; Hahn SM
J Surg Res; 2006 Oct; 135(2):323-30. PubMed ID: 16650871
[TBL] [Abstract][Full Text] [Related]
3. In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates.
Solonenko M; Cheung R; Busch TM; Kachur A; Griffin GM; Vulcan T; Zhu TC; Wang HW; Hahn SM; Yodh AG
Phys Med Biol; 2002 Mar; 47(6):857-73. PubMed ID: 11936174
[TBL] [Abstract][Full Text] [Related]
4. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.
Du KL; Mick R; Busch TM; Zhu TC; Finlay JC; Yu G; Yodh AG; Malkowicz SB; Smith D; Whittington R; Stripp D; Hahn SM
Lasers Surg Med; 2006 Jun; 38(5):427-34. PubMed ID: 16788929
[TBL] [Abstract][Full Text] [Related]
5. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
Verigos K; Stripp DC; Mick R; Zhu TC; Whittington R; Smith D; Dimofte A; Finlay J; Busch TM; Tochner ZA; Malkowicz S; Glatstein E; Hahn SM
J Environ Pathol Toxicol Oncol; 2006; 25(1-2):373-87. PubMed ID: 16566729
[TBL] [Abstract][Full Text] [Related]
6. Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.
Zhu TC; Dimofte A; Finlay JC; Stripp D; Busch T; Miles J; Whittington R; Malkowicz SB; Tochner Z; Glatstein E; Hahn SM
Photochem Photobiol; 2005; 81(1):96-105. PubMed ID: 15535736
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy in the canine prostate using motexafin lutetium.
Hsi RA; Kapatkin A; Strandberg J; Zhu T; Vulcan T; Solonenko M; Rodriguez C; Chang J; Saunders M; Mason N; Hahn S
Clin Cancer Res; 2001 Mar; 7(3):651-60. PubMed ID: 11297261
[TBL] [Abstract][Full Text] [Related]
8. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.
Zhu TC; Finlay JC; Hahn SM
J Photochem Photobiol B; 2005 Jun; 79(3):231-41. PubMed ID: 15896650
[TBL] [Abstract][Full Text] [Related]
9. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.
Dimofte A; Zhu TC; Hahn SM; Lustig RA
Lasers Surg Med; 2002; 31(5):305-12. PubMed ID: 12430147
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic monitoring of Chlorin e6-mediated photodynamic therapy using diffuse optical measurements.
Dong J; Toh HJ; Thong PS; Tee CS; Bi R; Soo KC; Lee K
J Photochem Photobiol B; 2014 Nov; 140():163-72. PubMed ID: 25146878
[TBL] [Abstract][Full Text] [Related]
11. Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome.
Wang HW; Putt ME; Emanuele MJ; Shin DB; Glatstein E; Yodh AG; Busch TM
Cancer Res; 2004 Oct; 64(20):7553-61. PubMed ID: 15492282
[TBL] [Abstract][Full Text] [Related]
12. Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.
Finlay JC; Zhu TC; Dimofte A; Stripp D; Malkowicz SB; Busch TM; Hahn SM
Photochem Photobiol; 2006; 82(5):1270-8. PubMed ID: 16808592
[TBL] [Abstract][Full Text] [Related]
13. The role of oxygen monitoring during photodynamic therapy and its potential for treatment dosimetry.
Woodhams JH; Macrobert AJ; Bown SG
Photochem Photobiol Sci; 2007 Dec; 6(12):1246-56. PubMed ID: 18046479
[TBL] [Abstract][Full Text] [Related]
14. Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.
Patel H; Mick R; Finlay J; Zhu TC; Rickter E; Cengel KA; Malkowicz SB; Hahn SM; Busch TM
Clin Cancer Res; 2008 Aug; 14(15):4869-76. PubMed ID: 18676760
[TBL] [Abstract][Full Text] [Related]
15. Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.
Busch TM; Wang HW; Wileyto EP; Yu G; Bunte RM
Radiat Res; 2010 Sep; 174(3):331-40. PubMed ID: 20726728
[TBL] [Abstract][Full Text] [Related]
16. Monitoring interstitial m-THPC-PDT in vivo using fluorescence and reflectance spectroscopy.
Kruijt B; van der Ploeg-van den Heuvel A; de Bruijn HS; Sterenborg HJ; Amelink A; Robinson DJ
Lasers Surg Med; 2009 Nov; 41(9):653-64. PubMed ID: 19802884
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy for prostate cancer--an emerging approach for organ-confined disease.
Moore CM; Emberton M; Bown SG
Lasers Surg Med; 2011 Sep; 43(7):768-75. PubMed ID: 22057504
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium.
Chou TM; Woodburn KW; Cheong WF; Lacy SA; Sudhir K; Adelman DC; Wahr D
Catheter Cardiovasc Interv; 2002 Nov; 57(3):387-94. PubMed ID: 12410519
[TBL] [Abstract][Full Text] [Related]
19. Foscan-based photodynamic treatment in vivo: correlation between efficacy and Foscan accumulation in tumor, plasma and leukocytes.
Maugain E; Sasnouski S; Zorin V; Merlin JL; Guillemin F; Bezdetnaya L
Oncol Rep; 2004 Sep; 12(3):639-45. PubMed ID: 15289849
[TBL] [Abstract][Full Text] [Related]
20. Optimisation of illumination for photodynamic therapy with mTHPC on normal colon and a transplantable tumour in rats.
Tsutsui H; MacRobert AJ; Curnow A; Rogowska A; Buonaccorsi G; Kato H; Bown SG
Lasers Med Sci; 2002; 17(2):101-9. PubMed ID: 12111593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
